Universal Beteiligungs und Servicegesellschaft mbH Makes New $2.34 Million Investment in Certara, Inc. (NASDAQ:CERT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 236,016 shares of Certara, Inc., valued at approximately $2.34 million, representing 0.15% ownership according to recent SEC filings.
• Analysts have a consensus target price of $15.29 for Certara, with ratings showing a mix of hold and buy opinions, while Barclays upgraded the stock to an "overweight" rating.
• Certara reported a quarterly EPS of $0.14, surpassing estimates, and experienced a 9.7% increase in revenue compared to the same quarter last year.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 236,016 shares of the company's stock, valued at approximately $2,337,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.15% of Certara as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CERT. Janney Montgomery Scott LLC purchased a new position in Certara during the first quarter worth approximately $120,000. First Trust Advisors LP purchased a new stake in Certara during the 4th quarter worth approximately $140,000. Illinois Municipal Retirement Fund lifted its position in Certara by 3.9% during the first quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock worth $591,000 after buying an additional 2,268 shares in the last quarter. Northern Trust Corp lifted its position in Certara by 14.0% during the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company's stock worth $9,340,000 after buying an additional 108,038 shares in the last quarter. Finally, Brown Advisory Inc. purchased a new stake in shares of Certara in the 1st quarter valued at approximately $238,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Down 3.0%

CERT stock traded down $0.30 during trading on Friday, hitting $9.54. 1,930,936 shares of the company's stock were exchanged, compared to its average volume of 1,485,978. The business has a 50-day moving average price of $11.04 and a two-hundred day moving average price of $11.83. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -477.00 and a beta of 1.42. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $15.69. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. As a group, equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. KeyCorp reduced their price target on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Morgan Stanley began coverage on shares of Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, Robert W. Baird raised their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.29.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.